Small Cell Lung Cancer Treatment Study
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy, when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC.
The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit.
In order to participate you must meet the following criteria:
- Have histologically or cytologically confirmed diagnosis of SCLC including the presence of neuroendocrine features by immunohistochemistry.
- Have extensive stage disease.
- Have at least one target lesion that is unirradiated and measurable by RECIST.
- Have an ECOG performance status of 0-2.
This is a partial list of elgibility requirements.